Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice  by Krishnamoorthy, Sriram et al.
Cellular Immunology 301 (2016) 30–39Contents lists available at ScienceDirect
Cellular Immunology
journal homepage: www.elsevier .com/ locate/yc immResearch paperRecombinant factor VIII Fc (rFVIIIFc) fusion protein reduces
immunogenicity and induces tolerance in hemophilia A micehttp://dx.doi.org/10.1016/j.cellimm.2015.12.008
0008-8749/ 2015 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: FVIII, factor VIII; rFVIIIFc, recombinant human factor VIII Fc; BDD,
B-domain deleted; FL-rFVIII, full length recombinant factor VIII; Treg, regulatory
T-cells; TNF-a, tumor necrosis factor-a; IFN-c, Interferon-c.
⇑ Corresponding authors.
E-mail addresses: sriram.krishnamoorthy@biogen.com (S. Krishnamoorthy),
haiyan.jiang.b@gmail.com (H. Jiang).Sriram Krishnamoorthy a,⇑, Tongyao Liu a, Douglas Drager a, Susannah Patarroyo-White a,
Ekta Seth Chhabra a, Robert Peters a, Neil Josephson b, David Lillicrap c, Richard S. Blumberg d,
Glenn F. Pierce a, Haiyan Jiang a,⇑
aHematology Research, Biogen, 115 Broadway, Cambridge, MA 02142, United States
bDivision of Hematology, University of Washington School of Medicine, Puget Sound Blood Center, Seattle, WA 98104, United States
cDepartment of Pathology and Molecular Medicine, Queen’s University, Kingston, Canada
dDivision of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
a r t i c l e i n f o a b s t r a c tArticle history:
Received 25 August 2015
Revised 25 November 2015
Accepted 28 December 2015
Available online 29 December 2015
Keywords:
Hemophilia A
Immune tolerance
Regulatory T cells
FcRn
Fc fusion protein
Immunogenicity
Factor VIIIAnti-factor VIII (FVIII) antibodies is a major complication of FVIII replacement therapy for hemophilia A.
We investigated the immune response to recombinant human factor VIII Fc (rFVIIIFc) in comparison to
BDD-rFVIII and full-length rFVIII (FL-rFVIII) in hemophilia A mice. Repeated administration of therapeu-
tically relevant doses of rFVIIIFc in these mice resulted in significantly lower antibody responses to rFVIII
compared to BDD-rFVIII and FL-rFVIII and reduced antibody production upon subsequent challenge with
high doses of rFVIIIFc. The induction of a tolerogenic response by rFVIIIFc was associated with higher per-
centage of regulatory T-cells, a lower percentage of pro-inflammatory splenic T-cells, and up-regulation
of tolerogenic cytokines and markers. Disruption of Fc interactions with either FcRn or Fcc receptors
diminished tolerance induction, suggesting the involvement of these pathways. These results indicate
that rFVIIIFc reduces immunogenicity and imparts tolerance to rFVIII demonstrating that recombinant
therapeutic proteins may be modified to influence immunogenicity and facilitate tolerance.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hemophilia A is an X-linked inherited bleeding disorder charac-
terized by spontaneous and traumatic bleeding [1]. The pathophys-
iologic features of this disease are associated with very low levels
or activity of factor VIII (FVIII) protein, arising because of genetic
defects (e.g. intron 22 inversion, large deletions) [2]. Currently,
the mainstay of treatment for hemophilia A is protein replacement
therapy [3], one major complication of which is development of
neutralizing antibodies, also known as inhibitors, to the infused
FVIII. The incidence of inhibitor formation is estimated at 20–30%
in all patients and at 30–40% in patients with severe disease.[4]
The development of inhibitors results from a complex multi-
faceted immune response involving both genetic and environmen-tal risk factors [5,6]. Several key molecules have been identified
that correlate with inhibitor formation in patients with hemophil-
ia. These include polymorphisms in the genes of the pro-
inflammatory cytokine tumor necrosis factor-a (TNF-a), the anti-
inflammatory cytokine interleukin-10 (IL-10), and the regulatory
T cell (Treg) marker cytotoxic T-lymphocyte antigen-4 (CTLA-4).
Higher levels of TNF-a and IL-10 have been demonstrated to corre-
late with higher incidence of inhibitors while higher CTLA-4
expression has been associated with a decreased incidence of inhi-
bitors [7–9]. However, the presence of splenic IL-10 positive T-cells
has also been associated with induction of FVIII tolerance in Hem A
mice [10,11].
Interventions to mitigate rFVIII immunogenicity in experimen-
tal models have included impairing co-stimulatory signals during
antigen presentation [12], inducing Tregs [13], presentation of FVIII
antigen by immature dendritic cells [14], and designing FVIII mole-
cules with fewer putative immunogenic epitopes. We therefore
sought to investigate the immunogenicity and immune tolerance
potential of recombinant FVIII Fc fusion protein (rFVIIIFc), which
was recently approved as a long-acting FVIII replacement therapy
for patients with hemophilia A. rFVIIIFc is composed of a single
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human IgG1 [15,16]. The Fc portion enables the molecule to inter-
act with the neonatal Fc receptor (FcRn), replicating the interaction
that rescues IgG from lysosomal degradation pathways, resulting
in a prolonged circulating half-life [17]. Immunomodulatory prop-
erties of Fc-containing fusion proteins have also been reported pre-
viously [18]. Of interest, two T-cell epitopes, termed Tregitopes,
have been identified in the Fc region of IgG1 that are capable of
activating Tregs [19,20].
In this report, we evaluated antibody and cellular immune
responses to rFVIIIFc in hemophilia A mice and interrogated the
pathways that potentially mediate rFVIIIFc immune tolerance.
We also investigated receptor dependent mechanisms to delineate
the possible downstream molecules that may promote the tolero-
genic activity of rFVIIIFc.2. Materials and methods
2.1. Mice
Hemophilia A (HemA) mice (C57BL/6) bearing a FVIII exon 16
knockout on a 129  B6 background [21] were obtained from Dr.
H. Kazazian (University of Pennsylvania). All animal procedures
used were approved by the Institutional Animal Care and Use Com-
mittee and performed based on guidelines from the Guide to the
Care and Use of Laboratory Animals.
2.2. Antibodies and reagents
Antibodies for FACS were obtained from BD Biosciences (Frank-
lin Lakes, NJ) or eBioscience (San Diego, CA). Recombinant human
B-domain-deleted FVIIIFc (rFVIIIFc), recombinant human B-
domain-deleted FVIII (Biogen in-house produced) used in ELISA,
rFVIIIFc IHH (amino acid substitutions I253A, H310A, H435A) and
rFVIIIFc N297A (single amino acid substitution in the Fc domain)
were produced as previously described [16]. Recombinant factor
VIII products BDD-rFVIII Xyntha (Wyeth Pharmaceuticals,
Philadelphia, PA) and full-length FVIII Advate (Baxter Healthcare
Corporation, Westlake Village, CA) were purchased and reconsti-
tuted according to manufacturers’ instructions.
2.3. Immunization/tolerance induction in mice
The study scheme for immunization and/or tolerance induction
is depicted in Fig. 1A and B. Three treatment groups consisting of
8–10 week old male HemA mice received intravenous doses of
50, 100, or 250 IU/kg on days 0, 7, 14, 21, 35, and 53. Blood samples
were collected by retro-orbital bleeding prior to dosing on days 0,
14, 21, 28 and 42. Plasmas were prepared, and anti-BDD-FVIII total
binding and neutralizing antibody levels were determined using
ELISA and Bethesda assay, respectively. Animals were euthanized
on day 56 by CO2 inhalation and spleens were dissected in sterile
PBS to isolate single cell suspensions (Miltenyi Biotec, Cologne,
Germany) and were either fixed in 3% formalin for FACS staining
or stored in dissociation buffer for RNA isolation (Roche Applied
Science, Indianapolis, IN). For immune tolerance studies, mice were
first injected with 50 IU/kg on days 0, 7, 14, 21, and 35, followed by
250 IU/kg of rFVIIIFc once weekly for 4 weeks. Rechallenged ani-
mals were tested for anti-BDD-FVIII antibody levels in plasma col-
lected on days 14, 21, and 28 post rechallenge. To test the immune
response to non-specific antigens, mice were injected subcuta-
neously on days 42 and 49 with DNP-OVA at 100 lg per mouse
in a 1:1 emulsion with Titermax Gold adjuvant from Sigma. Anti-
body responses to DNP and OVA were measured using an anti-DNP
Ig and anti-OVA Ig assay kit from Assay Diagnostics.2.4. Anti-BDD-FVIII antibody ELISA
The standard used for mouse IgG was a polyclonal pool of anti-
FVIII monoclonal antibodies prepared by mixing equal amount of
GMA8002 (A1), GMA8008 (C2), GMA8011 (C1), GMA8015 (A2),
GMA8016 (A2), GMA8005 (A1/A3) (Green Mountain Antibodies
Inc, Burlington, VT; FVIII domain epitopes in parenthesis). Detec-
tion antibody used was goat anti-mouse IgG-HRP. Absorbance
was measured on a Spectramax M2 plate reader (Molecular
Devices).
2.5. Bethesda assay for determining neutralizing antibody titers
Plasma samples were mixed with known concentrations of
BDD-rFVIII (in-house prepared) and incubated for 2 h at 37 C.
Residual FVIII activity in the mixture was then tested using a Coat-
est FVIII SP kit. The activity of FVIII was calculated against a stan-
dard curve generated with serially diluted BDD-rFVIII in naïve
HemA mouse plasma.
2.6. FACS analysis
Splenic lymphocytes and dendritic cells were stained for surface
and intracellular targets. For intracellular staining, cells were per-
meabilized with BD Fix-Perm solution (BD Biosciences) followed
by incubation with respective antibodies in the same buffer. Fluo-
rescence intensity was recorded using a BD FACS Canto II and anal-
ysis performed using FLOWJO software. For each sample 10,000
events were acquired on the flow cytometer. T-cells and dendritic
cells were gated based on CD4+ and CD11c+ staining, respectively.
2.7. Real time PCR and real time PCR-based array analysis
Total RNA was isolated (Roche Applied Science, Indianapolis, IN)
and reverse transcribed to cDNA (Qiagen, Hilden, Germany). PCR
primers for the tested genes were designed and purchased from
IDT technologies (Coralville, IA). SYBR green–based real-time PCR
was carried out using Quantitect system (Qiagen, Hilden, Ger-
many) or a PCR-based array for tolerance specific genes
(PAMM047Z, T-cell Anergy and Immune Tolerance PCR Array; SA
Biosciences, Frederick, MD) in an ABI 7900 Fast Block real-time
PCR machine (Applied Biosystems, Foster City, CA). Results were
analyzed using the 7500 software version 2.0.5 using the 2DCt rel-
ative quantification method [22], after normalization to GAPDH,
HPRT, Hsp90ab, beta-actin, and GusB. mRNAs that displayed
threshold cycles (Ct) >35 were excluded from the analysis.
2.8. T-cell proliferation and determination of interferon-c (IFN-c)
levels
HemA mice (8–10 week old) were injected with rFVIII products
once a week for 2 weeks. Seventy-two hours post the second injec-
tion mice were euthanized by CO2 inhalation and splenic T-cells
isolated using magnetic bead-based murine CD4+ T-cell isolation
kit (Miltenyi Biotec, Germany). T-cells were then labeled with
10 lM carboxyfluorescein diacetate succinimidyl ester (CFSE; Life
Technologies, Carlsbad, CA). Peritoneal macrophages were
obtained from naïve HemA mice (8–10 weeks old) by euthanasia
and peritoneal lavage with sterile PBS. Labeled T-cells from immu-
nized mice were co-incubated with naïve peritoneal macrophages
in the presence of BDD-rFVIII or vehicle or CD3/CD28 microbeads
(positive control; Miltenyi Biotec) in X-VIVO 15 medium (Lonza)
containing co-stimulatory antibodies namely anti-CD28 and anti-
CD49d (BD Biosciences), for 96 h at 37 C. IFNc levels in the culture
supernatant were measured using an ELISA kit from Meso Scale
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Fig. 1. rFVIIIFc induces immune tolerance to FVIII. A. Schematic for dosing regimen and analysis. HemA mice (8–10 weeks old) were injected with rFVIIIFc, BDD-rFVIII
(Xyntha), FL-rFVIII (Advate) or vehicle, at 50, 100, or 250 IU/kg once weekly for 4 weeks (days 0, 7, 14, and 21) followed by two injections 2 weeks apart (days 35 and 53).
Blood was collected by retro-orbital bleeding on days 0, 14, 21, 28, and 42, prior to the dosing, for isolating plasma and determining anti-BDD-FVIII total and neutralizing
antibody levels. On day 56, animals were sacrificed and spleens isolated to prepare single splenocyte suspensions. (B) Splenocytes were subjected to both FACS analysis and
PCR-based gene expression profiling as specified. (C) Total anti-BDD-FVIII IgG levels (lg/ml) in individual animals determined on day 42 (n = 8–13/group) (D) Neutralizing
antibody titers in individual animals on day 42 as determined using the Bethesda assay (n = 8–13/group). (E) HemA mice pretreated with 50 IU/kg of rFVIIIFc or vehicle, were
rechallenged with 250 IU/kg of rFVIIIFc on day 49, as described in Methods. Results presented are the total anti-FVIII IgG levels (lg/ml) determined on indicated days
(n = 8/group) (F) Neutralizing antibody titers (BU) on day 28 in rechallenged mice (n = 8/group). (G and H) HemA mice pretreated with 50 IU/kg of rFVIIIFc were challenged
with DNP-OVA in adjuvant (see Section 2) subcutaneously on days 42 and 49. Results presented are anti-OVA (G) and anti-DNP (H) immunoglobulin levels (units/mL)
compared to naïve mice receiving the two injections (control) and pre-bleeds of rFVIIIFc-tolerized mice (n = 5/group). The bar represents the median for each treatment
group. *p < 0.05; **p < 0.01; n.s. not significant by Mann–Whitney’s T-test.
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CFSE fluorescence intensity (MFI) using FACS (BD FACS CANTO II).
2.9. Treg mediated suppression of in vitro effector T-cell interferon-c
secretion
T-effector cells were isolated from HemA mice injected twice
with 250 IU/kg rFVIIIFc as described above. Tregs were isolated
from HemA mice injected with 5 weekly injections of 50 IU/kg
rFVIIIFc, using the murine CD4CD25 cell isolation kit (Miltenyi Bio-
tec, Germany). Antigen presenting CD90.2– cells were isolated from
naïve HemA mouse spleen using a magnetic bead based system
(Miltenyi Biotec, Germany). The cells were reconstituted at various
densities in vitro and activated with 10 nM of rFVIII in X-VIVO 15
medium (Lonza) containing co-stimulatory antibodies namely
anti-CD28 and anti-CD49d (BD Biosciences), for 96 h at 37 C. IFNc
levels in the culture supernatant were measured using an ELISA kit
from Meso Scale Devices (MSD).
2.10. Statistical analysis
Statistical analyses of results were carried out either using
unpaired 2-tailed student’s T-test or Mann–Whitney’s T-test. p-
values < 0.05 was considered to be significant.3. Results
3.1. rFVIIIFc evokes minimal antibody response at therapeutically
relevant doses and induces FVIII-specific tolerance
To evaluate the antibody responses to rFVIIIFc in comparison
with either BDD-rFVIII or full length rFVIII (FL-rFVIII), hemophilia
A (HemA) mice (8–10 weeks old) were treated with repeated intra-
venous administration of each drug at 50, 100, or 250 IU/kg
(Fig. 1A). Total binding antibodies (IgG) and neutralizing titers
against BDD-FVIII were determined weekly after day 14
(Fig. 1A and B). No antibodies were detected in the vehicle only
treated group (data not shown). The total anti-BDD-FVIII antibody
response was significantly lower in animals that received 50 IU/kg
and 100 IU/kg of rFVIIIFc compared to the same doses of BDD-
rFVIII and FL-rFVIII (Fig. 1C). The numbers of mice with detectable
anti-BDD-FVIII antibodies were 2 of 13 in the 50 IU/kg rFVIIIFc
group and 3 out of 10 in the 100 IU/kg rFVIIIFc group. In compar-
ison, anti-BDD-rFVIII antibodies developed in 8 out of 13 mice in
the 50 IU/kg BDD-rFVIII group and 8 of 10 mice in the 100 IU/kg
BDD-rFVIII group, and in 8 and 9 out of 10 mice in the 50 IU/kg
and 100 IU/kg FL-rFVIII groups, respectively. At 250 IU/kg, all three
treatments evoked high total anti-BDD-rFVIII antibody responses,
which were not significantly different among the three FVIII pro-
teins (Fig. 1C). Neutralizing antibodies to BDD-FVIII were detected
in none of 13 mice from the 50 IU/kg rFVIIIFc group and 1 of 10
mice from the 100 IU/kg rFVIIIFc group (Fig. 1D). In comparison,
a higher proportion of FL-rFVIII-injected animals (8 of 10) had
detectable neutralizing antibodies against BDD-FVIII at 50 IU/kg,
whereas 2 out of 13 mice injected with BDD-rFVIII had detectable
neutralizing antibody levels at this dose level. At 100 IU/kg, both
FL-rFVIII and BDD-rFVIII treated mice had a larger proportion of
animals with neutralizing antibodies against BDD-FVIII compared
to that observed with rFVIIIFc. At 250 IU/kg, all FVIII treatments eli-
cited high titers of neutralizing antibodies (Fig. 1D). These results
indicate that in HemA mice, rFVIIIFc at 50 and 100 IU/kg is less
immunogenic and results in less inhibitor formation compared to
FL-rFVIII and BDD-rFVIII.
To assess whether therapeutically relevant doses of rFVIIIFc
could induce immune tolerance to FVIII, HemA mice were pre-treated with 5 weekly injections of vehicle or 50 IU/kg rFVIIIFc, fol-
lowed by challenge with 250 IU/kg of rFVIIIFc. Mice pretreated
with 50 IU/kg of rFVIIIFc mounted a significantly lower BDD-FVIII
antibody response compared to animals pretreated with vehicle
(Fig. 1E). Notably, only 2 of 8 mice pretreated with 50 IU/kg
rFVIIIFc developed antibodies. In comparison, all the vehicle pre-
treated mice developed antibodies. rFVIIIFc pretreated mice also
had lower levels of neutralizing antibodies compared to vehicle
pretreated mice (Fig. 1F), indicating that repeat dosing of rFVIIIFc
at 50 IU/kg induced at least partial immune tolerance to FVIII in
HemA mice. The tolerance was specific for FVIII, since rFVIIIFc pre-
treated mice mounted a robust antibody response to the antigens
DNP and OVA, confirming that the mice did not develop general
immunosuppression following rFVIIIFc treatment (Fig. 1G and H).
3.2. Mechanisms of cellular tolerance in rFVIIIFc-treated HemA mice
To understand the lower immunogenicity and tolerogenic
effects of rFVIIIFc, we profiled splenic T-cells in rFVIIIFc-treated
mice. rFVIIIFc at 100 IU/kg induced a significantly higher percent-
age of CD4+CD25+Foxp3+ T cells consistent with Treg cells com-
pared to vehicle treated mice. Both BDD-rFVIII and FL-rFVIII
treatments (Fig. 2A) were comparable to each other and not signif-
icantly different from the vehicle control. In addition, rFVIIIFc
treatment also resulted in higher percentages of splenic CD4+ T-
cells expressing CD279 (PD-1) (Fig. 2B), a recognized tolerogenic
molecule [23]. Consistent with this, splenocytes from rFVIIIFc-
treated mice also had significantly lower percentages of CD4+ T-
cells positive for intracellular TNF-a compared to that observed
in BDD-rFVIIIFc or FL-RFVIII-treated mice (Fig. 2C). Further, we also
found that rFVIIIFc-treated mice exhibited higher percentages of
CD11c+CD274+ (PD-L1) dendritic cells (Fig. 2D). Taken together,
rFVIIIFc up-regulates both phenotypic Tregs and molecules associ-
ated with the immunosuppressive PD-L1:PD-1 pathway, which
potentially reduces immunogenicity and induces tolerance to FVIII.
Suppression of the immune response to rFVIII was further
demonstrated by the lack of recall response of splenic T-cells from
rFVIIIFc-treated mice to rFVIII presented in vitro. T-cells from
HemA mice treated with 50 IU/kg of rFVIIIFc did not show signifi-
cant proliferation ex-vivo in the presence of rFVIII compared to that
observed with T cells from control treated mice (Fig. 2E), with no
induction of IFN-c secretion (Fig. 2F). In contrast, T-cells from the
250 IU/kg rFVIIIFc treatment group showed a robust dose-
dependent increase in proliferation (Fig. 2E) and secretion of IFN-
c in response to rFVIII exposure ex-vivo (Fig. 2F). In addition, Tregs
isolated from mice treated with 5 weekly doses of 50 IU/kg
rFVIIIFc, was able to suppress IFNc production from effector CD4
+ T-cells isolated from mice receiving two weekly doses of
250 IU/kg rFVIIIFc (Fig. 2G). This suggests the existence of Treg
cells in spleen of mice receiving 50 IU/kg of rFVIIIFc that may par-
ticipate in the suppression of T-cell responses to rFVIII. In sum-
mary, these results from ex-vivo studies support the observations
from the splenic leukocyte profiling and suggest that rFVIIIFc treat-
ment resulted in suppression of T-cell responses to rFVIII.
3.3. rFVIIIFc activates multiple molecular determinants in promoting
tolerance
To identify the major pathways involved in the tolerance
induced by rFVIIIFc, we performed transcriptional profiling of
splenocytes from mice treated with vehicle, 50 IU/kg rFVIIIFc and
250 IU/kg rFVIIIFc, the latter being a dose which was not associated
with functional evidence of tolerance (Fig. 3A). The results demon-
strated the induction of several genes that are known to be
involved in multiple pathways of tolerance and anergy in mice
treated with 50 IU/kg rFVIIIFc (Fig. 3B). Results were validated with
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Fig. 2. rFVIIIFc induces Tregs and associated markers of tolerance. (A) Splenocytes from the 100 IU/kg group were stained for surface CD4 and CD25 followed by intracellular
Foxp3 and subjected to FACS analysis. Results represent percent splenocytes positive for CD4, CD25, and Foxp3 ± SEM (n = 7–9; *p < 0.05 vs. vehicle; yp < 0.05 vs rFVIIIFc; T-
test). (B) CD279 (PD-1) surface staining was determined by co-staining splenocytes from the 100 IU/kg groups with anti-CD279 and anti-CD4 and FACS analysis. Results
represent percent of CD4+C279+ splenocytes ± SEM (n = 7–9; *p < 0.05 vs. vehicle; yp < 0.05 vs rFVIIIFc; T-test). (C) Splenocytes from mice were co-stained for CD4 and
intracellular cytokine TNF-a. Results are percent splenocytes double positive for CD4 and TNF-a ± SEM (n = 6–10; *p < 0.05 vs. vehicle; yp < 0.05 vs rFVIIIFc; T-test). (D)
Dendritic cell surface expression of CD274 (PD-L1) was determined by staining splenocytes from the 100 IU/kg group for CD274 along with CD11c and MHC Class II (n = 7–9;
*p < 0.05 vs. vehicle; yp < 0.05 vs rFVIIIFc; T-test). (E) T-cell proliferation was measured using CFSE dye based dilution and FACS. CD4+ T-cells from splenocytes of mice injected
with 50 or 250 IU/kg of rFVIIIFc twice, one week apart, were loaded with CFSE and incubated with peritoneal macrophages collected from naïve HemA mice at indicated
concentrations of BDD-rFVIII as shown for 96 h at 37 C. Proliferation was measured as a function of decrease in CFSE MFI. Bars represent decrease in MFI of CFSE relative to
vehicle in T-cells ± SEM (*p < 0.05, T-test, n = 3–5). The anti-CD3/CD28 incubations were carried out on CD4+ T-cells derived from the 50 IU/kg group. (F) IFNc secretion profile
from the proliferation studies was measured by ELISA using a MSD (meso scale device) ELISA kit. Bars represent fold above vehicle of IFNc secretion ± SEM (*p < 0.05, T-test;
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Section 2). IFNc secretion was measured by ELISA using a MSD (meso scale device) ELISA kit. Bars represent fold above vehicle of IFNc secretion ± SEM (*p < 0.05 vs vehicle;
#p < 0.05 vs Teff, T-test; n = 4).
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CTLA-4, and IL-10 (Fig. 3C–E), anergy associated genes such as
Egr2, Dgka, and CBL-B (Fig. 3F–H), prostaglandin synthase 2
(PTGS2) and prostaglandin E2 receptor (PTGER2) (Fig. 3B) wereall up-regulated in the splenocytes from mice treated with 50 IU/
kg rFVIIIFc compared to vehicle and 250 IU/kg rFVIIIFc treated
mice. Conversely, pro-inflammatory molecules such as CCL3 and
STAT3 (Fig. 3B) were down-regulated in the 50 IU/kg rFVIIIFc
Veh 50IU 250IU
A. Heat Map     B.
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F. EGR-2    G. Dgka          H. Cbl-b I. TGF-β
* *
*
*
*
Fig. 3. Tolerogenic mechanisms activated by rFVIIIFc: (A) heat map depicting the expression profiles of all the genes in the real time PCR array among the three tested groups:
vehicle, 50 IU/kg and 250 IU/kg of rFVIIIFc. cDNA from each of the total splenocyte samples was used to monitor the expression of individual genes using a real time PCR array
consisting of genes focused on tolerance and anergy associated molecules (n = 8–11/group). (B) Expression profile of candidate genes that were identified as being up- or
down-regulated by the 50 IU/kg group in comparison with the 250 IU/kg group. Results shown here illustrate the fold change in expression of genes above vehicle group. The
cut-off for fold change in regulation was taken as 2, i.e., fold change above 2 was considered up-regulation and below 0.5 as down-regulation. All the candidate genes
belonging to the 50 IU/kg group shown here were significantly regulated (p < 0.05 vs. vehicle as well as the 250 IU/kg group; n = 8–11). Expression levels of some of the
candidates (C–H) are confirmed by real time PCR. (I) Real time PCR was carried out to determine levels of TGF-b mRNA transcript. Bars represent 2DCt values for the three
treatments (p < 0.05 vs. vehicle as well as the 250 IU/kg group; n = 8–11).
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TGF-b (Fig. 3I). The up-regulation of tolerogenic molecules such
as IL-10, TGF-b, IL-35 and IDO-1 (Suppl.), and down-regulation of
pro-inflammatory cytokines such as IL-17 (Suppl.) is consistent
with the induction of a tolerogenic microenvironment in response
to 50 IU/kg rFVIIIFc that is conducive to the suppression of anti-
body responses to rFVIII.3.4. Role of FcRn and Fcc receptors in rFVIIIFc-mediated immune
tolerance
Because of the presence of the Fc moiety, the gain of immune
tolerance function of rFVIIIFc may be attributed to the interaction
of rFVIIIFc with either FcRn or Fcc receptors, some of which are
associated with immunosuppression (namely the Fcc RIIb recep-
tor) (Fig. 4A). To dissect the receptor-mediated effect of rFVIIIFc,
we constructed two mutants – rFVIIIFc-N297A and rFVIIIFc-IHH
(I253A, H310A, H435A), which abrogate Fc binding to the Fcc
and FcRn receptors, respectively [24,25]. rFVIIIFc N297A exhibited
a comparable pharmacokinetic profile to that of rFVIIIFc in HemA
mice, whereas the circulating half-life of rFVIIIFc-IHH was reduced
relative to that of rFVIIIFc as expected, owing to the lack of recy-
cling via FcRn when these amino acids were mutated (data not
shown). Interestingly, neither mutant diminished the tolerogenic
effects of rFVIIIFc following repeated dosing of 50 IU/kg in HemA
mice. Thus, blocking either FcRn or FcRc interaction does not abro-
gate the immune tolerance properties of rFVIIIFc at this therapeu-
tic dose level in comparison to the consequences of lacking Fc
entirely as observed with BDD-rFVIII and FL-rFVIII which did result
in substantial antibody development at 50 IU/kg (Fig. 1C). In con-
trast, blocking FccR interactions (rFVIIIFc N297A), and to a lesser
extent blocking FcRn interactions (rFVIIIFc-IHH), attenuated the
antibody response in the high dose (250 IU/kg) treatment group
(Fig. 4B).
Although rFVIIIFc N297A and rFVIIIFc-IHH demonstrated
immunogenicity at 50 IU/kg that was comparable to the wild-
type rFIVIIIFc, both mutants, did exhibit a diminished induction
of CD25+/Foxp3+ T cells consistent with Tregs and lower percent-
ages of CD4+ T-cells that expressed intracellular IL-10, in the
spleen, which, nevertheless, were still significantly higher than
that observed in vehicle-treated animals (Fig. 4C and D). The per-
centages of splenic CD4+ T-cells expressing cytokines such as
TNF-a (Fig. 4E), IL-17 (Fig. 4F) and IFN-c (data not shown) were
comparable to those observed in vehicle- or rFVIIIFc-treated ani-
mals. Conversely, at 250 IU/kg, both mutants failed to induce toler-
ance markers over the background observed in control mice
(Fig. 4C and D). While rFVIIIFc and rFVIIIFc-IHH showed signifi-
cantly higher percentages of splenic T-cells producing proinflam-
matory cytokines (IL-17, TNF-a and IFN-c), rFVIIIFc N297A did
not increase proinflammatory cytokine positive T-cells to levels
above that observed in vehicle-treated mice at a dose of 250 IU/
kg (Fig. 4E and F and data not shown). Together, these studies sug-
gest a role for both FccR and FcRn in the tolerogenic pathways
observed with rFVIIIFc.4. Discussion
Replacement therapy with recombinant proteins, though bene-
ficial to most patients, may be hampered by the formation of anti-
drug antibodies, counteracting the effectiveness of treatment [26].
FVIII replacement therapy for hemophilia A is an example, where
30% of patients develop neutralizing antibodies. In addition to
regimens aiming to achieve immune tolerance induction, there
are initiatives that seek to minimize the immunogenicity potential
of FVIII. Herein, we report that rFVIIIFc, which was developed toprolong the circulating half-life of FVIII by genetic fusion of BDD-
FVIII and the Fc portion of human IgG1, diminished the antibody
response to FVIII in a mouse model of hemophilia A. In addition,
our results suggest that the reduced immunogenicity is due to
the establishment of a tolerogenic microenvironment in the spleen
of HemA mice at therapeutically relevant doses of rFVIIIFc and
dependent upon the Fc domain. Consistent with our findings in
the preclinical animal model, it is of interest to note that immune
tolerance induction with rFVIIIFc has successfully eradicated anti-
FVIII inhibitors in 3 children with high antibody titers (peaked at
16-422 BU), including 1 child with the highest titer who previously
failed ITI with rFVIII (Lynn M. Malec et al., Abstract from the 57th
Annual Meeting of the American Society of Hematology 2015).
The concept of IgG as a tolerogenic carrier and as a means to
reduce the antigenicity of the cargo has been demonstrated several
decades ago [27,28]. Apart from half-life extension, Fc fusion pro-
teins are also associated with immunomodulatory properties that
result in the inhibition of immune responses to linked antigens
[29,30]. For example, a fusion protein composed of the IgG1 heavy
chain linked with the interphotoreceptor retinoid binding protein
(IRBP) antigen, expressed in B-cells, was able to protect mice from
experimental autoimmune uveitis directed at the IRBP antigen
[31]. Similarly, tolerance to FVIII was also demonstrated by engi-
neering fusion proteins that contained the C2 or A2 domains of
FVIII together with IgG [20]. It was recently demonstrated that
Fc-mediated transplacental delivery of immunodominant FVIII
domains fused with the Fc region of IgG induced tolerance to FVIII
[18]. In the present study, we demonstrated that the Fc domain is
responsible for suppressing the immune response towards rFVIII, a
highly immunogenic protein in mice, at therapeutic doses (see
Fig. 5).
Specific polymorphisms within the TNF-a and IL-10 genes have
been linked to a higher incidence of inhibitor formation in patients
[7,8]. Although higher IL-10 levels have been correlated with
increased antibody formation in humans, the presence of splenic
IL-10-positive T-cells has also been associated with tolerogenic
pathways in HemA mice [10]. Similarly, higher levels of secreted
IL-10 and TGF-b and lower levels of pro-inflammatory cytokines
such as IL-17 have been demonstrated to extend tolerance to rFVIII
in animal models [11]. In our study, rFVIIIFc treatment resulted in a
percentage of splenic TNF-a+ CD4+ T cells that was similar to
untreated animals and significantly lower than that observed in
mice that received similar doses of BDD-rFVIII and FL-rFVIII. In
contrast, splenocytes from mice receiving therapeutically relevant
doses of rFVIIIFc showed upregulation in mRNA levels of anti-
inflammatory cytokines such as IL-10, TGF-b, and IL-35. Thus, ther-
apeutically relevant doses of rFVIIIFc prevented the expression of
inflammatory cytokines and promoted the expression of cytokines
associated with tolerance.
Furthermore, upregulation of tolerance-related markers such as
Foxp3, CD25, PD-1 (CD279), and CTLA-4 was identified. Together
with the cytokine changes, these data suggest the induction of
functional tolerance pathways mediated by regulatory T cells with
therapeutically relevant doses of rFVIIIFc (see Fig 3). Treg cells have
been shown to induce tolerance to self-antigens as well as to
injected protein therapeutics, including FVIII in murine models of
hemophilia [32]. Naturally occurring as well as induced splenic
regulatory T cells were able to block antibody responses to FVIII
in HemA mice [33,34]. CD4+Foxp3+ Treg cells, along with higher
percentages of cells positive for surface markers such as CD25
and CTLA-4, were also responsible for immune tolerance to FVIII
induced by plasmid-mediated FVIII gene therapy in HemA mice
[35]. In another model, rapamycin-induced Treg cells were capable
of imparting tolerance to rFVIII in HemA mice. The immune toler-
ance pathways in this rapamycin-induced model showed pheno-
typic evidence of Treg cell induction along with up-regulation of
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Fig. 4. rFVIIIFc signals via FcRn and/or Fcc receptors to induce immune tolerance to rFVIII. (A) Hypothesis for the possible receptor dependent mechanisms for rFVIIIFc to
induce tolerance. (B) Total anti-FVIII IgG levels on day 42 in HemA mice injected with 50 or 250 IU/kg of rFVIIIFc, rFVIIIFc-N297A and rFVIIIFc-IHH, in comparison with BDD-
rFVIII (Xyntha) or FL-rFVIII (Advate). Results illustrated here are anti-BDD-FVIII IgG levels (lg/ml) and the median bar is depicted for each group in the study (n = 8–13;
*p < 0.05; **p < 0.01; Mann–Whitney test). (C–F) FACS analysis for markers indicated from splenocytes of mice injected with 50 or 250 IU/kg of rFVIIIFc or mutants. Bars depict
% splenocytes for the marker tested + S.E.M. (*p < 0.05; T-test; n = 6–11).
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and IL-10 transcripts in splenocytes [13].
Key molecular determinants of tolerogenic dendritic cells [36]
observed in our investigations included PD-L1 and IDO-1. IDO-1
is a central tolerogenic molecule activated in dendritic cells that
can skew an immune response towards tolerance [36]. In a previ-
ous report, transposon based co-delivery of IDO-1 and FVIII genesattenuated inhibitor formation in HemA mice [37]. Our results
support the notion that therapeutically relevant doses of rFVIIIFc
promote multiple cell types that lead to suppression of immuno-
genicity and promoting tolerance to FVIII.
The impact of interactions with either FcRn using the non-
binding mutant, rFVIIIFc-IHH, or with FccR, using the non-
binding mutant rFVIIIFc N297A, were investigated. Despite the lack
Fig. 5. Working model for mechanism of action of rFVIIIFc in induction of immune tolerance to rFVIII.
38 S. Krishnamoorthy et al. / Cellular Immunology 301 (2016) 30–39of binding to these receptors, both mutant FVIII proteins retained
reduced immunogenicity at low doses in comparison to FL-rFVIII
and BDD-rFVIII. However, both mutants exhibited a markedly
attenuated induction of tolerogenic molecules implicating them
in the tolerogenic pathways at therapeutic doses, although the
levels of these molecules were still significantly higher than those
observed in vehicle-treated mice. Conversely, at high doses, both
rFVIIIFc and rFVIIIFc-IHH were comparably immunogenic, partly
due to an increase in the levels of pro-inflammatory cytokines
and lack of induction of Treg cells, whereas preventing the FccR
interaction with the N279A rFVIIIFc tempered the production of
pro-inflammatory cytokines although it was not sufficient to
induce tolerance. The results suggest that the tolerogenic path-
ways activated by rFVIIIFc may involve a combination of these
two signaling mechanisms, i.e., via FcRn and/or FccR, presumably
FccRIIb, and potentially others such as the presence of Tregitopes
within Fc [19].
The FccRIIb receptor is an immunosuppressive Fc receptor that
has been demonstrated in multiple systems to counteract stimula-
tory signals [38]. The N297A mutation in the Fc region of IgG abol-
ishes the interaction of Fc with the FccRIIb receptor. FccRIIb
signaling and induction of CD4+Foxp3+ cells have been reported
in the establishment of oral and mucosal tolerance to foreign anti-
gens in mice [39,40], and FccRIIb-deficient mice exhibit dimin-
ished Treg induction against foreign antigens in vivo [40]. These
studies have implicated a role for both B-cells and dendritic cells
which are known to harbor this immunomodulatory receptor
[39,40]. Moreover, co-culture of dendritic cells derived from
FccRIIb knockout mice, with CD4+ T-cells led to higher prolifera-
tion and pro-inflammatory IFN-c and IL-2 secretion in vitro [40].
In agreement with these results, our studies showed attenuated
Treg marker levels in low dose N297A treated mice. Of interest,
mice treated with high doses of rFVIIIFc N297A did not result in
higher levels of splenic T-cells expressing pro-inflammatory
cytokines as did rFVIIIFc, likely due to the lack of interaction of
rFVIIIFc N297A with stimulatory Fcc receptors, suggesting the con-
tribution of T-cell cytokines to the immunogenicity observed with
high doses of rFVIIIFc.5. Conclusion
In summary, rFVIIIFc proved to be less immunogenic than FL-
rFVIII and BDD-rFVIII at therapeutically relevant doses and pro-
moted the development of phenotypic Tregs and a tolerogenic
microenvironment in the spleen of HemA mice. Mechanistically,
this tolerogenic effect is partly mediated by the Fc receptors Fcc
and FcRn, which may act in concert with other elements. In con-
trast, at high doses there was a loss of these tolerogenic properties,
owing, at least in part, to the presence of inflammatory cytokines.
Moreover, pretreatment with therapeutically relevant, tolerogenic
doses of rFVIIIFc resulted in blunting of the immune response to
high doses of rFVIIIFc. Our studies therefore not only provide sup-
port for the ability of rFVIIIFc to reduce immunogenicity and
induce functional tolerance but also may help guide the evaluation
of future treatments of rFVIIIFc in hemophilia A patients that aim
to prevent immune responses to FVIII.Funding
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